StockpollyBeta
Get App
Popularity #2,199
ZYME · NASDAQ · Biotechnology

Zymeworks (ZYME)

Develops antibody medicines and earns royalties from partner-run therapies.

$26.93
vs last close−0.63 (−2.30%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue171710191631274928325
Cost of revenue000000000230
Gross profit171710191631274928105
504048625053534950454747
Research & development332632293637363436312,40832
171511614161715141415,06919
General & administrative171511614161715141415,06919
Other expenses001517000000−17,430−5
Operating income−33−23−38−43−34−22−26−1−22−44−47−42
64655433431−3
Interest income556554334333
Interest expense000000000020
Other non-operating income00−15−170000−4−3−33
Income before tax−28−19−32−38−30−18−222−18−41−46−45
Income tax expense1−500060010−20
Net income from continuing operations−29−14−32−38−30−24−232−20−41−44−45
Net income−29−14−32−38−30−24−232−20−41−44−45
EPS, basic−$0.41−$0.20−$0.42−$0.49−$0.39−$0.31−$0.30$0.03−$0.26−$0.55−$0.59−$0.62
EPS, diluted−$0.41−$0.20−$0.42−$0.49−$0.39−$0.31−$0.30$0.03−$0.26−$0.55−$0.59−$0.62
Weighted average shares, basic707176767676757576757573
Weighted average shares, diluted717176767676757776757573
EBITDA−27−20−21−23−32−19−223−16−40−41−43
Depreciation & amortization732334333232
EBIT−33−23−23−26−34−22−26−1−18−41−44−45